S. Zildjian
-
- Cancer Treatment and Pharmacology 3
- Lung Cancer Research Studies 3
- HER2/EGFR in Cancer Research 3
-
- Multiple Myeloma Research and Treatments 5
-
- Monoclonal and Polyclonal Antibodies Research 3
-
- Endometrial and Cervical Cancer Treatments 3
-
- Cancer Genomics and Diagnostics 6
-
- Genetic factors in colorectal cancer 5
- Co-authors
- James J. O’LearyAsher Chanan‐KhanJeffrey L. WolfSteven WeitmanMecide GhariboSundar JagannathSikander AilawadhiAlbert Qin
- Partner nations
- United StatesUnited KingdomSpain
In The Last Decade
S. Zildjian
20 papers receiving 193 citations
Peers
Comparison fields: 5 of 31
- Oncology 145
- Hematology 57
- Radiology, Nuclear Medicine and Imaging 110
- Genetics 23
- Obstetrics and Gynecology 13
Countries citing papers authored by S. Zildjian
This map shows the geographic impact of S. Zildjian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Zildjian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Zildjian more than expected).
Fields of papers citing papers by S. Zildjian
This network shows the impact of papers produced by S. Zildjian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Zildjian. The network helps show where S. Zildjian may publish in the future.
Co-authorship network
The 25 scholars most cited alongside S. Zildjian, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2022 | 2 | |
| 2 | 2022 | 0 | |
| 3 | 2022 | 15 | |
| 4 | 2022 | 1 | |
| 5 | 2022 | 7 | |
| 6 | 2014 | 7 | |
| 7 | 2014 | 14 | |
| 8 | 2011 | 13 | |
| 9 | 2011 | 27 | |
| 10 | 2010 | 12 | |
| 11 | 2010 | 32 | |
| 12 | Clinical experience of IMGN901 (BB-10901) in patients with small cell lung carcinoma (SCLC) | 2009 | 8 |
| 13 | 2009 | 17 | |
| 14 | 2009 | 13 | |
| 15 | 2008 | 8 | |
| 16 | 2008 | 4 | |
| 17 | 2008 | 1 | |
| 18 | A phase I and pharmacokinetic study of a CanAg-targeted immunoconjugate, HuC242-DM4, in patients with CanAg-expressing solid tumors | 2007 | 2 |
| 19 | 2007 | 12 | |
| 20 | 2006 | 2 |
About S. Zildjian
S. Zildjian is a scholar working on Hematology, Oncology and Cancer Research, having authored 21 papers that have together received 200 indexed citations. Recurring topics across this work include Cancer Genomics and Diagnostics (6 papers), Multiple Myeloma Research and Treatments (5 papers), Genetic factors in colorectal cancer (5 papers), Endometrial and Cervical Cancer Treatments (3 papers), Cancer Treatment and Pharmacology (3 papers), Lung Cancer Research Studies (3 papers), HER2/EGFR in Cancer Research (3 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). The work is most often cited by research in Oncology (145 citations), Hematology (57 citations) and Radiology, Nuclear Medicine and Imaging (110 citations). S. Zildjian has collaborated with scholars based in United States, United Kingdom and Spain. Frequent co-authors include James J. O’Leary, Asher Chanan‐Khan, Jeffrey L. Wolf, Steven Weitman, Mecide Gharibo, Sundar Jagannath, Sikander Ailawadhi, Albert Qin, Robert Vescio and Juan Garcia. Their work appears in journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.